# MERÍSTEM

# Earnings Plummet as Costs Outweigh Topline Growth

#### **Stronger Demand Propels Topline Growth**

The agricultural sector (with the livestock subsector inclusive) witnessed a strong recovery in 2021 (Agricultural GDP growth: 25.88%YoY, Livestock GDP growth: 1.71YoY%). In our opinion, the robust demand for animal feed by poultry and other livestock farmers underscored this growth in the livestock subsector. Hence, animal feed players such as Livestock Feeds Plc recorded strong revenue growth in the period. On a regional basis, the company benefitted significantly from the Southwestern market as it delivered the highest sales growth (+56.06% YoY), closely followed by revenue from the Eastern market (+22.35% YoY). This masked the lower topline recorded in the Northern market (-21.22% YoY). In our <u>9M:2021</u> report, we highlighted some of the challenges responsible for the consistent decline in sales from this region. On a cumulative note, the firm's topline came in at NGN14.64bn (vs NGN11.18bn in 2020FY). For year 2022, we project a 13.00% YoY revenue growth to NGN16.54bn in 2022FY. We anticipate heightened demand of animal feeds, hinged on a strong demand for animal products, to drive this expansion in revenue. Albeit the lingering security challenges in the Northern market continues to pose a downside risk to our outlook for revenue growth in the region.

#### **Cost Pressures Subdue Profitability Metrics**

During the year, the firm's production cost (+32.02%YoY) expanded faster than revenue. This heightened cost pressure can be attributed to dependence on importation of raw materials (wheat and maize), foreign exchange volatility and the high inflationary environment. Consequently, cost to sales ratio worsened to 89.22% (vs. 88.50% in 2020FY). Operating expenses also came in higher at NGN0.73bn in 2021FY (vs NGN0.69bn), attributable to the increase in administrative expenses (+39.05%YoY). The strong revenue growth bolstered the operating profit, as it expanded by 25.81% YoY to NGN0.86bn.

Finance cost increased significantly by 113.04% to NGN0.30bn, resulting in a contraction in the firm's interest coverage ratio to 2.89x (vs 4.90x in 2020FY). The surge in finance cost is attributable to the expansion (+273.84%) in the company's total debts to NGN7.45bn (from NGN1.99bn in 2020FY). Overall, Profit Before Tax (PBT) grew by 3.49% YoY to NGN0.57bn. On the other hand, the Profit After Tax (PAT) declined by 14.60% YoY to NGN0.43bn. This was as a result of the higher tax expense in the period. The company paid off some tax expenses from its minimum tax owed in previous years. Going forward, we anticipate the high inflationary environment and the current volatility in the FX market to remain the major downside risks to earnings potential. Hence, we forecast a decline in the bottomline by -6.67% to NGN0.41bn in 2022FY.

#### **Increased Borrowings Impacts Firm's Leverage**


In 2021FY, we note that the firm's cash position spiked to an all-time high of NGN0.34bn following proceeds from debt amounting to (NGN7.45bn) in the period. However, the cash ratio only improved slightly to 0.04x (vs 0.02x in 2020FY; African peers' average cash ratio: 0.24x). In our view, we consider the company to be highly levered when compared to African peers (LIVESTOCK's leverage ratio: 4.33x vs 3.12x in 2020FY; vs average of 2.42x of its African peers).

#### Recommendation

We project a 2022FY expected EPS of NGN0.13 and a target PE of 11.64x. This yields a target price of NGN1.56 and a downside potential of -9.53% based on the closing price on April 13, 2022. Hence, we rate the ticker a **HOLD**.

Company LIVESTOCK Valuation (Trailing) EPS 0.14 **BVPS** 0.83 P/E 15.45 P/BV 2.05 Target PE 11.64x Dec-2022 Exp. EPS 0.13 Dec 2022 Target price 1.56 **Current Price** 1.72 Up/Downside Potential -9.53% Ratings HOLD **Key metrics** ROE 18.78% ROA 4.97% Net margin 2.94% Asset Turnover 1.62x Leverage 4.33x Yr Hi 2.15 Yr Lo 1.42 YTD return -20.93% Beta 1.48 Adjusted Beta 1.32 Shares outstanding 3.00bn 5.10bn Market cap [NGN] Financial year end December Most Recent Period (MRP) 2021FY LIVESTOCK - NGXASI 2.00

April 12, 2022



+234 (812) 110 5615

mosunmolaadeoye@meristemng.com



April 12, 2022

# **Chart 1: Sensitivity Analysis**

Sensitivity Analysis of Dec-2022 Target Price to key model inputs					Min	0.39		
	EPS					Max	2.74	
		0.03	0.08	0.13	0.18	0.23	_	
	11.54x	0.39	0.97	1.54	2.12	2.70	-	
Torget DE	11.59x	0.39	0.97	1.55	2.13	2.71		
Target PE	11.64x	0.39	0.97	1.56	2.14	2.72		
	11.69x	0.39	0.98	1.56	2.15	2.73		
	11.74x	0.40	0.98	1.57	2.16	2.74	_	

Financial Highlights and Forecasts (NG	N billion)						
Profit & Loss Account	2020A	2021A	2022F	2023F	2024F	2025F	2026FY
Revenue	11.18	14.64	16.54	18.69	21.12	24.29	27.94
Cost of sales	9.74	12.90	14.75	16.96	19.26	22.05	25.25
Gross profit	1.44	1.74	1.80	1.73	1.87	2.24	2.69
Operating expense	0.68	0.73	0.78	0.83	0.88	0.93	0.99
Operating profit	0.69	0.86	0.89	0.78	0.86	1.18	1.56
Finance cost	0.14	0.30	0.36	0.38	0.39	0.59	0.89
РВТ	0.55	0.57	0.53	0.41	0.47	0.60	0.69
РАТ	0.50	0.43	0.40	0.33	0.34	0.42	0.46
Balance Sheet	2020A	2021A	2022F	2023F	2024F	2025F	2026FY
Property, Plant and Equipment	0.84	0.78	0.76	0.75	0.75	0.74	0.73
Total Debt	1.99	7.45	3.83	3.09	2.47	1.87	1.26
Total Assets	6.47	10.83	7.22	6.55	6.06	5.66	5.33
Total Equity	2.07	2.50	2.39	2.32	2.28	2.48	2.23
Total Current Liabilities	4.40	8.28	4.78	4.18	3.73	3.37	3.06
Non-Current Liabilities	0.00	0.04	0.04	0.04	0.04	0.04	0.04
Total Liabilities	4.40	8.33	4.83	4.23	3.78	3.42	3.10
Financial Ratios	2020A	2021A	2022F	2023F	2024F	2025F	2026FY
Gross Margin	12.88%	11.91%	10.86%	9.28%	8.84%	9.24%	9.63%
Operating Margin	6.14%	5.89%	5.39%	4.17%	4.07%	4.85%	5.60%
Net Margin	4.50%	2.94%	2.42%	1.76%	1.61%	1.72%	1.64%
Return on Asset	9.58%	4.97%	4.44%	4.77%	5.39%	7.14%	8.34%
Return on Equity	27.63%	18.78%	16.38%	13.92%	14.77%	18.48%	20.48%
Asset Turnover	1.29	1.62	2.40	2.97	3.60	4.42	5.24
Financial Leverage	3.12	4.33	3.02	2.82	2.66	2.52	2.39
Current Ratio	1.28	1.21	1.51	1.57	1.62	1.68	1.74
Quick Ratio	0.12	0.17	0.16	0.10	0.07	0.04	0.03

(Q1- First-Quarter); (H1- First-Half); (H2- Second Half) (FY- Full Year) (F- Forecast)



April 12, 2022

# **Contact Information**

	Brokerage and Retail Services topeoludimu@meristemng.com	(+234 905 569 0627)
	isaaconaolapo@meristemng.com	(+234 803 234 8275)
	contact@meristemng.com	
	Investment Banking/Corporate	Finance
	rasakisalawu@meristemng.com	(+234 806 022 9889)
	seunlijofi@meristemng.com	(+234 808 536 5766)
	Wealth Management	
	funmilolaadekola-daramola@meristemng.com	(+234 805 498 4522)
	crmwealth@meristemng.com	
	Tel : +234 01 738 9948	
	Registrars	
	muboolasoko@meristemregistrars.com	(+234 803 324 7996)
	martinaosague@meristemregistrars.com	(+234 802 303 1783)
	www.meristemregistrars.com	
	Tel: +23401-280 9250	
	Trust Services	
	damilolahassan@meristemng.com	(+234 803 613 9123)
	trustees@meristemng.com	· · · ·
	Group Business Development	
	saheedbashir@mersitemng.com	(+234 802 454 6575)
	ifeomaogalue@meristemng.com	(+234 802 3942967)
	info@meristemng.com	
	Client Services	
	adefemitaiwo@meristemng.com	(+234 803 694 3034)
	blessingogwuche@meristemng.com	(+234 706 896 5173)
	car@meristemng.com	
	Investment Research	
	timchanggwatau@meristemng.com	(+234 703 188 3322)
	research@meristemng.com	
orporate websites:	www.meristemng.com www.meriste	mwealth.com www.meristemregistrars.com
ristom Research ca	n also be accessed on the following platforms:	
	n also be accessed on the following platforms: al: research@meristemng.com	
omberg: MERI <go></go>		

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

**FactSet:** www.factset.com



## **Analyst's Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

(1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and

(2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.

(3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

**Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

#### **Investment Ratings**

#### **Fair Value Estimate**

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodology. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

#### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

#### **Ratings Specification**

- **BUY:** Target Price of the stock is above the current market price by at least 10 percent
- HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.
- **SELL:** Target Price of the stock is more than **10 percent** below the current market price.



# Nigeria | Equities | LIVESTOCK | 2021FY

#### Definitions

**Price Targets:** Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

**Asset allocation:** The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

#### **Movements in Price Target**

#### Company Name: Livestock Feeds Plc

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
15-Nov-2021	2.19	2.71	2.33	SELL	BUY
12-Apr-2022	1.70	2.58	1.56	BUY	HOLD

## **Company disclosures**

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
Livestock Feeds Plc	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



April 12, 2022

# **Conflict of Interest**

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

### **Important Disclosure**

**For U.S. persons only:** This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

#### Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2022 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited